# Safety of Stopping Pancreatic Enzyme Replacement Therapy in Children With Improved Pancreatic Function After Highly Effective Modulator Therapy

> **NCT07632768** · PHASE4 · COMPLETED · sponsor: **Indiana University** · enrollment: 17 (actual)

## Conditions studied

- Cystic Fibrosis (CF)
- Pancreatic Insufficiency
- Pancreas Disease
- Exocrine Pancreatic Insufficiency
- Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis
- CFTR Gene Mutation

## Interventions

- **DRUG:** Discontinuation of Pancreatic Enzyme Replacement Therapy

## Key facts

- **NCT ID:** NCT07632768
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-03
- **Primary completion:** 2026-01-21
- **Final completion:** 2026-01-21
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07632768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07632768, "Safety of Stopping Pancreatic Enzyme Replacement Therapy in Children With Improved Pancreatic Function After Highly Effective Modulator Therapy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07632768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*